Novo Nordisk A/S Sponsored ADR (NVO)
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term.
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four years on average in patients with diabetes and established heart disease, with or without chronic kidney disease.
1 no-brainer biotech giant to buy in April
The advent of weight-loss drugs, primarily semaglutide, proved to be an immense boon for biotech giants — primarily Novo Nordisk and Eli Lilly.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk says compounded drugs are hurting Wegovy sales
CNBC's Karen Gilchrist discusses the impact of U.S. compounded weight loss drugs and potential tariffs on obesity drug giant Novo Nordisk.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment. "I'm very confident about CagriSema," he told shareholders at the firm's Annual General Meeting in Copenhagen, Denmark.
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.
Novo Nordisk should steady nerves by restating growth targets alongside Q1 results
JP Morgan expects Novo Nordisk (NYSE:NVO) to hold the line on its 2025 growth targets when it reports first-quarter results, saying a reaffirmation of guidance would help calm nerves after a sluggish start to the year for weight-loss drug Wegovy in the US. Analyst Richard Vosser forecasts sales of DKr77.1bn, around 4% below Bloomberg consensus estimates, largely due to lower expectations for both Wegovy and diabetes treatment Ozempic.
Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal
Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.
Why Novo Nordisk Stock Dipped on Thursday
Novo Nordisk's (NVO -2.13%) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like the company ingested some of its own treatment.
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting Wegovy sales. CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal action against companies it believes to be violating its intellectual property.
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. Eli Lilly.
